Author(s):
Mohathasim Billah A, Rajamohamed H, Mohamed Akram Ali S, Porkodi M, Vikashini S, Lida Sajimon
Email(s):
rajahaithar@jssuni.edu.in
DOI:
10.52711/0974-360X.2024.00507
Address:
Mohathasim Billah A1, Rajamohamed H2*, Mohamed Akram Ali S3, Porkodi M4, Vikashini S2, Lida Sajimon5
1Department of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamil Nadu, India.
2Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India.
3Department of Pharmacy Practice, Sri Shanmugha College of Pharmacy, Sankari, Tamil Nadu, India.
4Department of Clinical Pharmacology, St. Peter's Medical College Hospital and Research Institute, Hosur, Tamil Nadu, India.
5Department of Pharmacology, School of Pharmacy, Vishwakarma University, Pune, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 7,
Year - 2024
ABSTRACT:
Statins are generally used to prevent coronary artery disease and dramatically reduce the levels of low-density lipoproteins compared to previously employed methods. A known side effect of statins is rhabdomyolysis typically manifests elevation in creatine kinase. Here we discuss a 63-year-old man who presented with left-sided chest pain spreading to the left arm, trouble breathing, vomiting, and elevated perspiration was diagnosed with Acute Myocardial Infarction and was treated with simvastatin in a Lalpet Healthcare Center, Tamilnadu, India. Later, developed rhabdomyolysis, a known and rare side effect of statin, which was treated with 500mL/h of saline solution, 500mL/h of 5% glucose solution, and 50mmol of sodium bicarbonate. The main therapeutic objective is to prevent the causes that lead to Acute Kidney Injury. Muscle toxicity is the common ADR of increased doses of statin therapy worldwide; in that case, statin therapy should be stopped immediately, and patients need to receive symptomatic care if they experience significant muscle complaints or rhabdomyolysis. This treatment comprises administering sufficient fluid resuscitation, keeping track of urine output, and treating electrolyte abnormalities, particularly hyperkalemia. For statin overdose, there is no known remedy. Patients need to start retaking low-dose statins after recovering from an overdose. This instance emphasizes the significance of understanding complicated drug therapy interactions in an era of growing multi-drug practices and the discouragement that can occur when these interactions are disregarded. Reporting this study is more significant because rhabdomyolysis is a severe and fatal condition caused by the statins drugs used to treat and prevent coronary artery disease.
Cite this article:
Mohathasim Billah A, Rajamohamed H, Mohamed Akram Ali S, Porkodi M, Vikashini S, Lida Sajimon. Statin-induced Rhabdomyolysis and its Management – A Case Report. Research Journal of Pharmacy and Technology. 2024; 17(7):3241-5. doi: 10.52711/0974-360X.2024.00507
Cite(Electronic):
Mohathasim Billah A, Rajamohamed H, Mohamed Akram Ali S, Porkodi M, Vikashini S, Lida Sajimon. Statin-induced Rhabdomyolysis and its Management – A Case Report. Research Journal of Pharmacy and Technology. 2024; 17(7):3241-5. doi: 10.52711/0974-360X.2024.00507 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-7-40
REFERENCES:
1. Brown AJ, Sharpe LJ. Cholesterol Synthesis. In: Biochemistry of Lipids, Lipoproteins and Membranes. Elsevier 2016; 327-358. doi:10.1016/B978-0-444-63438-2.00011-0
2. Ashna A, Jeena S, Vidhya PV, Venkateswaramurthy. N, Sambathkumar. R. Statins: Pleiotropic Effect. Research J. Pharm. and Tech. 2016; 9(7): 977-981. doi: 10.5958/0974-360X.2016.00187.6
3. Kishan L. Jadhav, Priyanka R. Kapare, Divya V. Khairmode, Chaitali H. Keskar1, Farida Shaikh, Shradda Sawant, Akash S. Mali. Genetic Insights of Cholesterol and Atherosclerosis: Complex Biology. Asian J. Pharm. Res. 2018; 8(3): 175-184. doi: 10.5958/2231-5691.2018.00031.X
4. Puja S. Gaikwad, Dhanshri U.Gadhave, Nayna V. Pimpodkar, Trushali A. Mandhare. Pleiotropic Effects of Statins. Asian J. Res. Pharm. Sci. 2015; 5(1): Jan.-March 55-58. doi: 10.5958/2231-5659.2015.00009.0
5. Sree Lekshmi. R. S, P. Shanmugasundaram. Neuroprotective Properties of Statins. Research J. Pharm. and Tech 2018; 11(8): 3581-3584. doi: 10.5958/0974-360X.2018.00659.5
6. Yazan Batineh, Qutaiba Ahmed Al Khames Aga, Kawthar Faris Nassir, Tharwat I Sulaiman, Ali Abbas Al-Gharawi, Jawad I Rasheed, Zaid Al Madfai, Mutaz A. Sheikh Salem, Luma Ahmed Al Khames Aga, Manhal Yasseen Rijab Agha, Eamon Abdullah. Fenofibrate and Statins in Patients with COVID-19. Research Journal of Pharmacy and Technology. 2022; 15(11): 5132-8. doi: 10.52711/0974-360X.2022.00863
7. Shivani Gupta, Rashi Jain, Suman Kapur. Statins: A Review of Wonder Drug from Fungus. Research J. Pharm. and Tech. 2014; 7(10): Oct. 1201-1207.
8. Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: pros and cons. Med Clin (Barc) 2018; 150(10): 398-402. doi:10.1016/j.medcli.2017.11.030
9. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services task force. JAMA - J Am Med Assoc. 2016; 316(19): 2008-2024. doi:10.1001/jama.2015.15629
10. Sizar O, Khare S, Jamil RT, Talati R. Statin Medications 2023. http://www.ncbi.nlm.nih.gov/pubmed/32956597
11. Senthilkumar T, Tamilselvi A. Risk factors of Cardiovascular Disease in Adolescents: A Systematic Review. Asian J. Nursing Education and Research. 2021; 11(1): 151-156. doi: 10.5958/2349-2996.2021.00039.2
12. Bansal AB, Cassagnol M. HMG-CoA Reductase Inhibitors 2023. http://www.ncbi.nlm.nih.gov/pubmed/30586774
13. Khandelwal Alisha, Sharma Tripti. Repurposing statins as a potential ligand for estrogen receptor alpha via molecular docking. Research Journal of Pharmacy and Technology. 2021; 14(7): 3757-2. doi: 10.52711/0974-360X.2021.00650
14. Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol 2010; 22(4): 422-429. doi:10.1016/j.ceb.2010.05.004
15. Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annu Rev Med. 2018; 69: 133-145. doi:10.1146/annurev-med-042716-091351
16. Line RL, Rust GS. Acute exertional rhabdomyolysis. Am Fam Physician. 1995; 52(2): 502-506. http://www.ncbi.nlm.nih.gov/pubmed/7625324
17. Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxford Med case reports. 2018; 2018(3): omx104. doi:10.1093/omcr/omx104
18. Samir Derouiche, Taissir Cheradid, Messaouda Guessoum. Heavy metals, Oxidative stress and Inflammation in Pathophysiology of Chronic Kidney disease - A Review. Asian J. Pharm. Tech. 2020; 10(3): 202-206. doi: 10.5958/2231-5713.2020.00033.1
19. Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol 2014; 78(3): 454-466. doi:10.1111/bcp.12360
20. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61(3): 141-152. doi:10.1097/00005792-198205000-00002
21. de Meijer AR, Fikkers BG, de Keijzer MH, van Engelen BGM, Drenth JPH. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003; 29(7): 1121-1125. doi:10.1007/s00134-003-1800-5
22. Holt S, Moore K. Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol 2000; 8(2): 72-76. doi:10.1159/000020651
23. Reis ND, Michaelson M. Crush injury to the lower limbs. Treatment of the local injury. J Bone Joint Surg Am 1986; 68(3): 414-418. http://www.ncbi.nlm.nih.gov/pubmed/3949835.
24. Selvaraj Sudhakar, Jibi Paul, Senthil Selvam P, Mahendranath P. Serum Creatine Kinase Response on Exercise Induced Delayed Onset Muscle Soreness: A Pilot Single Blind Randomized Clinical Trial. Research J. Pharm. and Tech. 2020; 13(8): 3638-3642. doi: 10.5958/0974-360X.2020.00643.5
25. Vanholder R, Sever MSDD, EREK E, LAMEIRE N. Rhabdomyolysis. J Am Soc Nephrol 2000; 11(8): 1553-1561. doi:10.1681/ASN.V1181553
26. K. Sai Girisha, Mohan Ram. A Prospective Study on Efficacy of Mircera for Treating Anemia Associated with Chronic Kidney Disease. Research J. Pharm. and Tech. 2017; 10(11): 3807-3809. doi: 10.5958/0974-360X.2017.00691.6